Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Cumberland Pharmaceuticals (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07), Zacks reports. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Apotex transaction closed July 1, delivering $100 million in cash at closing, with an additional $11 million expected from inventory and transition payments and a potential $10 million milestone payment.
• Cumberland declared a $1.50-per-share special dividend totaling approximately $22 million while retaining enough capital to fund operations for more than five years and maintain over $50 million in reserves.
• The company is pivoting fully toward its ifetroban pipeline, with anticipated 2026 milestones including systemic sclerosis top-line results, interim efficacy data from the idiopathic pulmonary fibrosis study, and further regulatory guidance for Duchenne muscular dystrophy.
• Management cited encouraging clinical progress: ifetroban’s DMD study produced supportive biomarker findings, the systemic sclerosis trial completed enrollment, and a Vanderbilt oncology study reported fewer metastatic recurrences and metastasis-related deaths in the treatment arm.
• Following the divestiture, Cumberland will no longer receive revenue from its commercial brands and will operate primarily as a development-stage biopharmaceutical company; second-quarter operating loss was $3.1 million and net loss was $4.1 million.

Cumberland Pharmaceuticals Stock Performance

Cumberland Pharmaceuticals stock opened at $7.80 on Wednesday. The firm has a fifty day simple moving average of $6.36 and a two-hundred day simple moving average of $4.76. Cumberland Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $8.09. The company has a market capitalization of $116.81 million, a PE ratio of -15.91 and a beta of 0.08. The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25.

Cumberland Pharmaceuticals Announces Dividend

The firm also recently announced a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were issued a dividend of $1.50 per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new stake in Cumberland Pharmaceuticals during the 4th quarter valued at $1,358,000. Dimensional Fund Advisors LP increased its position in shares of Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after acquiring an additional 27,980 shares during the period. Bridgeway Capital Management LLC raised its stake in shares of Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after acquiring an additional 4,200 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth about $192,000. Institutional investors own 15.51% of the company’s stock.

Analyst Ratings Changes

CPIX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.